Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioblastoma 1Astrocytoma 1

Interventions

Specimen Handling 123Magnetic Resonance Spectroscopy 117Cyclophosphamide 109pembrolizumab 88Radiotherapy 83Nivolumab 73Cisplatin 68fludarabine 65Biopsy 60Carboplatin 59Standard of Care 49Radiosurgery 45Gemcitabine 44Paclitaxel 42Dexamethasone 42Radiation 39Doxorubicin 39Rituximab 38Blood Specimen Collection 37Bevacizumab 37venetoclax 36Cytarabine 36Surveys and Questionnaires 35fludarabine phosphate 33Capecitabine 33Temozolomide 31Radiotherapy, Intensity-Modulated 31Practice Guidelines as Topic 31Ipilimumab 28Interviews as Topic 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × vocimagene amiretrorepvec × 30 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡